Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces it has concluded a commercialization agreement in northern Europe for its innovative rescue therapy for epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam, covering Germany, the UK, Denmark, Sweden, Finland and Norway.
